CYP2B9 inhibitors are a specialized class of chemical compounds designed to selectively target and inhibit the activity of the CYP2B9 enzyme, a member of the cytochrome P450 superfamily. This enzyme plays a crucial role in the oxidative metabolism of a variety of substrates, including both endogenous molecules such as hormones, fatty acids, and cholesterol derivatives, as well as exogenous substances like drugs and environmental toxins. CYP2B9 functions primarily by catalyzing the monooxygenation of its substrates, a process in which an oxygen atom is incorporated into the substrate molecule. This modification typically increases the polarity of the substrate, making it more soluble and facilitating its subsequent metabolism or excretion. The activity of CYP2B9 is particularly significant in the liver, where it contributes to the detoxification processes that protect the organism from potentially harmful compounds.
Inhibitors of CYP2B9 are generally small molecules designed to bind to the enzyme's active site, thereby preventing it from catalyzing the oxidation of its substrates. These inhibitors may function by occupying the enzyme's substrate-binding pocket, effectively blocking the access of substrates to the catalytic site, or by inducing conformational changes that diminish the enzyme's catalytic efficiency. The development of CYP2B9 inhibitors involves a thorough understanding of the enzyme's three-dimensional structure, particularly the regions involved in substrate recognition and binding. By inhibiting CYP2B9, researchers can gain insights into the enzyme's specific role in various metabolic pathways and its interaction with other members of the cytochrome P450 superfamily. The study of CYP2B9 inhibitors is essential for understanding the enzyme's contribution to the broader network of metabolic processes, highlighting the intricate balance that these enzymes maintain in metabolizing a diverse array of chemical entities within the body. This research not only deepens our understanding of cytochrome P450 enzymes but also sheds light on the complex mechanisms that regulate metabolism and detoxification in biological systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Abiraterone | 154229-19-3 | sc-460288 | 10 mg | $276.00 | ||
Abiraterone inhibits CYP2B9, disrupting its monooxygenase activity and influencing the metabolism of steroids and xenobiotics. | ||||||
Fluvoxamine | 54739-18-3 | sc-207697 | 25 mg | $321.00 | 1 | |
Fluvoxamine acts as a direct inhibitor of CYP2B9, impacting its heme binding and monooxygenase functions, thereby modulating pathways related to xenobiotic metabolism. | ||||||
Ticlopidine Hydrochloride | 53885-35-1 | sc-205861 sc-205861A | 1 g 5 g | $32.00 $99.00 | 2 | |
Ticlopidine is a potent CYP2B9 inhibitor, influencing heme binding and monooxygenase activities, leading to alterations in xenobiotic catabolic processes and related pathways. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole disrupts CYP2B9 activities, including heme binding and monooxygenase functions, impacting pathways associated with xenobiotic metabolism and organic acid processing. | ||||||
Ciprofloxacin | 85721-33-1 | sc-217900 | 1 g | $43.00 | 8 | |
Ciprofloxacin serves as a direct inhibitor of CYP2B9, affecting heme binding and monooxygenase activities, thereby modulating xenobiotic metabolism and related processes. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine acts as a direct inhibitor of CYP2B9, impacting heme binding and monooxygenase activities, leading to alterations in xenobiotic metabolism and related pathways. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole disrupts CYP2B9 activities, including heme binding and monooxygenase functions, impacting pathways associated with xenobiotic metabolism and organic acid processing. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $66.00 $160.00 | 2 | |
Miconazole serves as a direct inhibitor of CYP2B9, affecting heme binding and monooxygenase activities, thereby modulating xenobiotic metabolism and related processes. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Terbinafine inhibits CYP2B9 directly, disrupting heme binding and monooxygenase functions, leading to alterations in xenobiotic metabolism and related cellular processes. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Clotrimazole acts as a direct inhibitor of CYP2B9, impacting heme binding and monooxygenase activities, leading to alterations in xenobiotic metabolism and related pathways. | ||||||